Nanox (NASDAQ:NNOX) reported a 37% increase in second-quarter 2026 revenue to $4.2 million, but its GAAP net loss widened to $55.5 million following a $40.7 million impairment charge, while cash declined and the company said it intends to continue raising funds.
Key Investor Takeaways
- Q2 revenue increased to $4.2 million from $3.0 million, with acquired Nanox Health IT contributing $0.9 million.
- Nanox (NASDAQ:NNOX) recorded a $40.7 million non-cash impairment related to its AI solutions business, contributing to a GAAP net loss of $55.5 million.
- Adjusted EBITDA loss widened to $11.3 million from $10.4 million a year earlier, showing that operating losses remain substantial despite revenue growth.
- Cash and equivalents declined to $31.4 million from $60.0 million at year-end 2025, although Nanox subsequently raised $8.5 million in gross proceeds.
- Commercial milestones included the first patient scans at the initial Nanox Imaging Network site, insurance reimbursement for scans and further Nanox.ARC and Nanox.AI activity.
Why NNOX Stock Is in Focus
Nanox’s Q2 revenue growth was accompanied by continued losses and a substantial impairment of its AI-related intangible assets.
Revenue reached $4.2 million, up from $3.0 million in the comparable period. Teleradiology generated $3.0 million, AI and Software Solutions contributed $1.0 million, and imaging systems and OEM services generated $0.2 million.
The acquisition of Nanox Health IT, consolidated from November 2025, accounted for $0.9 million of quarterly revenue and was the primary driver of the year-over-year increase. The acquired business also put more than 20 new projects live during the first half of 2026.
The headline GAAP loss was heavily affected by a $40.7 million impairment charge triggered by the company’s share-price decline and reduced forecasts for revenue and operating results. The charge reduced the fair value of intangible assets associated with the AI solutions business, excluding Nanox Health IT, to $1.9 million.
The impairment was non-cash and did not affect liquidity, but it pushed the GAAP net loss to $55.5 million from $14.7 million a year earlier. On a non-GAAP basis, the net loss was $11.6 million versus $10.9 million, while adjusted EBITDA loss increased to $11.3 million from $10.4 million.
Why This Matters for Investors
The quarter presents investors with competing signals: Nanox is generating commercial activity across several parts of its platform, but its financial profile continues to reflect significant operating losses and capital requirements.
The company began scanning patients at its first Nanox Imaging Network location in Philadelphia and said it has started receiving insurance reimbursement for those scans. It also expanded its U.S. distribution network to ten partners and progressed additional Nanox.ARC capital equipment agreements.
However, Nanox said there has been no material change in the number of Nanox.ARC systems at various stages of deployment compared with previously reported levels. Imaging systems and OEM services also accounted for only $0.2 million of quarterly revenue, making conversion of the existing pipeline into active clinical use an important measure of future execution.
Liquidity is another central issue. Cash and equivalents declined from $60.0 million at the end of 2025 to $31.4 million at June 30. Nanox subsequently raised $8.5 million in gross proceeds through a registered-direct offering and its at-the-market programme and said it intends to continue raising capital from various sources.
Cost reductions could partially change that trajectory. The restructuring of South Korean operations includes moving substantially all chip manufacturing to qualified third parties and reducing the workforce by 67%. Nanox expects approximately $0.9 million of restructuring expenses and around $2 million in annual savings beginning in 2027.
The pending securities class action introduces an additional uncertainty. The case remains at an early stage, and Nanox said it cannot currently assess the probability of a loss or reasonably estimate potential costs and damages.
What to Watch Next
Investors can watch whether Nanox converts more Nanox.ARC systems from its pipeline into deployed, revenue-generating clinical installations and whether its first imaging network site demonstrates further reimbursement and patient-volume progress.
Cash usage and additional fundraising will also remain important given the company’s $31.4 million quarter-end cash position and stated intention to raise further funds.
Other developments to monitor include the commercial contribution from Nanox Health IT, progress toward a potential new CMS reimbursement pathway, the impact of Korean restructuring on expenses and any material developments in the securities litigation.